💥#EndometrialCancer TKI/IO safety data & AE mgmt webinar 💥┈┈┈ w @DrMMurphy & @drteplinsky ┈┈┈🔹#CME info 👉 bit.ly/3Vqtabi 👈 @BonumCE ┈┈┈🔸Supported by edu grants from Eisai & @Merck 🔹#TumorBoardTuesday #gyncsm #OncTwitter twitter.com/i/broadcasts/1…
1/#TumorBoardTuesday #OncTwitter

#1:Answer #PreTest❓🔗bit.ly/EC_AEs_TBTpre
#2:Tell us who u are👇
#3:🔁Retweet & tag colleagues

🧧#CME ℹ️bit.ly/3Vqtabi
Supported by edu grants from Eisai & @Merck

🟢Where r u in your career?
3/#TumorBoardTuesday #BonumCE #OncTwitter #GynCSM #gynonc #EndometrialCancer

🟠Earn 🆓 #CME 🏆
🟠#CME ℹ️🔗bit.ly/3YRDkog

📸 Faculty disclosures & important CME info 👇
3/#TumorBoardTuesday #gyncsm #OncTwitter

🤔Missed the #EndometrialCancer #MedTweetorial earlier this wk?
🤯Feeling left behind?

Don't fret, it's here📍
4/#TumorBoardTuesday #BonumCE #OncTwitter #GynCSM #gynonc

⌚️Understanding timing of onset helps us better understand, differentiate, & manage TKI & ICI-related AEs 👇
5/ Thanks #TumorBoardTuesday & #gyncsm!

🏆Claim #CME bit.ly/3hYxu3R
⬇️Answer #PostTest👇

🔴#PostTest Q1️⃣
📊Diarrhea, nausea, & vomiting are common GI tox associated w pembro + lenvatinib combo tx
🔴Which other tox may occur if these GI tox r not effectively managed?
6/#TumorBoardTuesday #BonumCE #GynCSM #EndometrialCancer
#CME 🔗bit.ly/3hYxu3R

🔴#PostTest Q 2️⃣
📊During tx w pembro + lenva, pt develops grd 3 diarrhea
🛑Lenva held
💊Loperamide Rx
Grade3️⃣diarrhea persists

🔴Which is the appropriate next step for this pt?
7/#TumorBoardTuesday #GynCSM

🔴#PostTest Q3️⃣
📊Pt receiving pembro + lenva combo for past 12m
🗓@ f/u presented w persistently high levels of TSH
🟥Lenva withheld, but TSH levels remain high (>10mIU/L)

🔴What is the most appropriate next step in the mgmt of this pt?
8/#TumorBoardTuesday #BonumCE #OncTwitter #GynCSM #gynonc #EndometrialCancer

#CME🔗bit.ly/3hYxu3R

🔴#PostTest Q4️⃣
During treatment w pembro + lenva, pt develops grade 3 HTN
🔴What is the most effective mgmt strategy for this patient? (CS = corticosteroid)

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with #TumorBoardTuesday

#TumorBoardTuesday Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @TumorBoardTues

Jan 19
1/#TumorBoardTuesday #OncTwitter

🗓️TODAY🗓 w @DrMMurphy & @DrTeplinsky
🎥#EndometrialCancer - Mnging TKI/IO AEs

#CMEℹ️ bit.ly/3Vqtabi
Support by edu grants from Eisai & @Merck

🚨Be ready @ 8p ET/5p PT
✅Answer #PreTest👇
🔁RT & tag 🩺

🟢Where r u in your career?
2/#TumorBoardTuesday #OncTwitter #GynCSM #gynonc
#CME🔗bit.ly/3YRDkog

🟢#PreTest Q 1️⃣
📊Diarrhea, nausea, & vomiting are common GI toxicities associated w pembro + lenvatinib combo therapy

🟢Which other tox may occur if these GI toxicities are not effectively managed?
3/#TumorBoardTuesday #GynCSM #EndometrialCancer
#CME🔗bit.ly/3YRDkog

🟢#PreTest Q 2️⃣
📊During tx w pembro + lenvatinib, pt develops grade 3 diarrhea
🛑Lenva held
💊Loperamide Rx
Grade3️⃣diarrhea persists

🟢What is the next step for this pt?
(cs=corticosteroid)
Read 5 tweets
Jan 18
1/#OncTwitter #TumorBoardTuesday #MedTweetorial 🧵

#EndometrialCancer AE deep dive🤿
🧪Trial results
🔬Tox for TKI-ICI
w @DrMMurphy @MeganLeigh127 & us!

🆓#CME @BonumCe🔗bit.ly/3VBGJEJ
Supported by edu grants from Eisai & @Merck

🟢What's your specialty?
2/#TumorBoardTuesday #BonumCE #OncTwitter #gyncsm #gynonc #EndometrialCancer #MedTweetorial

🆓 CME > full info➕ref list🗒️& program archive
👉bit.ly/3VBGJEJ

🔑#CME info👇 Image
3/#TumorBoardTuesday #BonumCE #OncTwitter #GynOnc #gyncsm #EndometrialCancer

🟢Which I/O +🎯tx combo is FDA approved for treatment of advanced or metastatic #EndometrialCarcinoma?

nivo = nivolumab
dostarlimab = dostarlimab-gxly
pembro = pembrolizumab
Read 27 tweets
Jan 16
@MPishvaian #GI23
Coming at you from #TumorBoardTuesday
The TOP 🎯💊abstracts for ASCO-GI 2023

➡️Starting with MSI-H cancers:
✅Path CR neoadj ICI MSI-H GI Cancers
👁️L Pappas, Abs 43, Pos B18

✅A Ph 2 trial of toripalimab in adv tumors with POLE/POLD1🧬mut
👁️Y Jin, Abs 802, Pos M17
@MPishvaian #GI23
➡️Exciting updates in HER2➕Cancers

✅A Ph 2 trial of trast➕pertuz vs. iri➕cetuximab for HER2➕mCRC: SWOG S1613
👁️KPS Raghav, Abs 140, Pos G18

✅Zanidatamab➕chemo as 1⃣st-line Tx for HER2➕met GE jxn AdenoCa
👁️Ea Elimova, Abs 347, Pos E8
@MPishvaian #GI23
➡️Several CRC-specific🎯💊trials:

✅A Ph Ib trial of dabraf➕tramet➕iri➕cetux in BRAF V600E-mut mCRC
👁️Y Chen, Abs 156, Pos H15

✅A TAPUR trial update of Olaparib for pts with ATM-mut mCRC
👁️D Behl, Abs 122, Pos F19
Read 6 tweets
Dec 15, 2022
1/🛎️#TumorBoardTuesday #OncTwitter #NephTwitter
#RenalCell wk continues🔁

🗓️Thu 12.15 @ 8p ET

⚙️Mnging AEs w TKI/IO combos

#CME ℹ️🔗bit.ly/3iLN6aX
Supported by edu grants from Eisai & @Merck
🚨Be ready 4 tmrw!
✅Answer #PreTest polls👇
🔁Retweet & tag colleagues🩺
2/ 🏆Claim 🆓#CME 🔛 bit.ly/3iLN6aX

Answer Pre Polls Qs 👇today
🟢Where r u in your career?
3/ #TumorBoardTuesday #RenalCell #NephTwitter #MedTwitter #BonumCE

#CME🔗bit.ly/3FbuEQx

🟢#PreTest Q 1️⃣
📊 Which of the following is a common high-grade toxicity associated with the use of TKIs in the management of metastatic RCC?
Read 6 tweets
Dec 13, 2022
1/ #OncTwitter #NephTwitter #TumorBoardTuesday
#RenalCell #MedTweetorial🧵
w @brian_rini @shilpaonc @katy_beckermann

🦺TKI/IO safety data
🥽Tox to look 4
⛑AE mgmt

🆓#CME @BonumCe🔗bit.ly/3VDaK81
Support by edu grants from Eisai & @Merck

🟢What's your specialty?
2/ #TumorBoardTuesday #BonumCE #RenalCell #OncTwitter #NephTwitter
🆓#CME info ➕ full ref list🗒️ 👉 bit.ly/3VDaK81

✳️The critical elements👇 Image
3/ #TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter

🟢 Which of the following TKI/IO combo regimens is 🚫NOT approved by the FDA for the frontline mgmt of #RenalCell carcinoma?
Read 27 tweets
May 30, 2022
#TumorBoardTuesday #ASCO2022

📢@ASCO is only a few days away & we really wanted to put out our top abstracts to👀for

🙏note - we viewed several thousand titles - so we definitely may have missed some‼️
👉And these are not in any particular order

✅But enjoy, RT, and reply😀
#TumorBoardTuesday #ASCO2022
"Emerging"🎯💊
✅Dr. Jones👨‍🏫the Ph2 FAKTION trial of fulv/capi vs fulv/placebo for Breast Ca
➡️Capi⬆️mOS by 6 mos
➡️This⬆️jumped to 19 ms if the tumor harbored PIK3CA or AKT1 activating OR PTEN inactivating🧬mutations
🔎Breast Ca Oral Abstract # 1005
#TumorBoardTuesday #ASCO2022
"Emerging"🎯💊
✅Dr. Rixe👨‍🏫PhI data4⃣OBT076, an ADC🎯the CD205/Ly75 Ag - a receptor⬆️on immunosuppressive dendritic cells
➡️1⃣PR & 6⃣SD out of 2⃣0⃣pts
➡️Near CR in 2⃣pts who then had pembro
🤔Why wasn't☝️more than a poster❓
🔎Abs 3028, Poster 20
Read 32 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(